|  |  |
| --- | --- |
| Journal Name: | [**Asian Journal of Research in Medical and Pharmaceutical Sciences**](https://journalajrimps.com/index.php/AJRIMPS) |
| Manuscript Number: | **Ms\_AJRIMPS\_141051** |
| Title of the Manuscript: | **Evaluation of Prostate-Specific Antigen in Relation to Lipid Profile and Atherogenic Indices in Adult Males in Abuja** |
| Type of the Article |  |

|  |
| --- |
| **PART 1: Comments** |
|  | **Reviewer’s comment****Artificial Intelligence (AI) generated or assisted review comments are strictly prohibited during peer review.** | **Author’s Feedback** (It is mandatory that authors should write his/her feedback here) |
| **Please write a few sentences regarding the importance of this manuscript for the scientific community. A minimum of 3-4 sentences may be required for this part.** | This manuscript addresses a clinically significant topic, exploring the play between prostate- specific antigen (PSA), lipid profile, and atherogenic indices in adult males in Abuja, Nigeria. By focusing on an African population, it adds important local data to the global literature, where similar regional evidence is often lacking. The study’s findings on the significant association between LDL-C and elevated PSA levels have impact on enhancing prostate disease risk stratification, in resource-limited settings. Additionally, its highlights on metabolic profiling as a complementary tool to PSA testing could inform broader screening strategiesand public health interventions. |  |
| **Is the title of the article suitable?****(If not please suggest an alternative title)** | The title is generally suitable and clearly reflects the content of the study.**Suggested Alternative (optional)**:“Association Between Prostate-Specific Antigen Levels and Lipid Metabolism in Adult Nigerian Males: A Cross-Sectional Analysis”This alternative may provide a more specific academic framing, but the current title is acceptable. |  |
| **Is the abstract of the article comprehensive? Do you suggest the addition (or deletion) of some points in this section? Please write your suggestions here.** | **Comprehensiveness**: The abstract concisely summarizes the study’s background, aim, methodology, key findings, and conclusion.**Suggested Improvements**:Consider briefly mentioning the number of participants in the abstract to reinforce methodological rigor.Clarify that atherogenic indices were not predictive but still analyzed to ensure conceptual completeness.Replace the vague term "may improve prostate risk assessment" with a more precise phrase such as "could serve as adjunctive screening markers." |  |
| **Is the manuscript scientifically, correct? Please write here.** | **Scientific Validity of the Manuscript**The manuscript is scientifically sound, methodologically appropriate, and statistically well- analyzed.The cross-sectional design is properly justified for the research objective.The discussion provides appropriate contextualization with relevant literature and demonstrates awareness of both strengths and limitations.However, while the inclusion/exclusion criteria are robust, stratified analysis beyond age (e.g., BMI, comorbidities) could add depth in future studies. |  |
| **Are the references sufficient and recent? If you have suggestions of additional references, please mention them in the review form.** | **References Adequacy**: The references cited are relevant, generally recent (within the last 10 years), and from reputable journals.**Suggestions for Additional References**:Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7-30. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/31912902)]Alpert PF. New Evidence for the Benefit of Prostate-specific Antigen Screening: Data From 400,887 Kaiser Permanente Patients. Urology. 2018 Aug;118:119-126. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/29772218)] |  |

|  |  |  |
| --- | --- | --- |
|  | Gunes S, Hekim GN, Arslan MA, Asci R. Effects of aging on the male reproductive system. J Assist Reprod Genet. 2016 Apr;33(4):441-54. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818633/)] [[PubMed](https://pubmed.ncbi.nlm.nih.gov/26867640)]US Preventive Services Task Force. Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, Davidson KW, Doubeni CA, Ebell M, Epling JW, Kemper AR, Krist AH, Kubik M, Landefeld CS, Mangione CM, Silverstein M, Simon MA, Siu AL, Tseng CW. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018 May 08;319(18):1901-1913. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/29801017)]Albertsen PC. Prostate cancer screening with prostate-specific antigen: Where are we going? Cancer. 2018 Feb 01;124(3):453-455. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/29231972)]Leal J, Welton NJ, Martin RM, Donovan J, Hamdy F, Neal D, Noble S, Lane A, Wolstenholme J. Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study. Cancer Epidemiol. 2018 Feb;52:99-105. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/29278842)]Özkan TA, Cebeci OÖ, Çevik İ, Dillioğlugil Ö. Prognostic influence of 5 alpha reductase inhibitors in patients with localized prostate cancer under active surveillance. Turk J Urol. 2018 Mar;44(2):132-137. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832374/)] [[PubMed](https://pubmed.ncbi.nlm.nih.gov/29511582)]Kearns JT, Faino AV, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Zheng Y, Lin DW. Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. EurUrol. 2018 May;73(5):706-712. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6064187/)] [[PubMed](https://pubmed.ncbi.nlm.nih.gov/29433973)]Olsson H, Nordström T, Jäderling F, Egevad L, Vigneswaran HT, Annerstedt M, Grönberg H, Eklund M, LantzA. Incorporating Magnetic Resonance Imaging and Biomarkers in Active Surveillance Protocols - Results From the Prospective Stockholm3 Active Surveillance Trial (STHLM3AS). J Natl Cancer Inst. 2021 May 04;113(5):632-640. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096373/)] [[PubMed](https://pubmed.ncbi.nlm.nih.gov/32866231)]Amin A, Scheltema MJ, Shnier R, Blazevski A, Moses D, Cusick T, Siriwardena A, Yuen B, van Leeuwen PJ, Haynes AM, Matthews J, Brenner P, O'Neill G, Yuen C, Delprado W, Stricker P, Thompson J. The Magnetic Resonance Imaging in Active Surveillance (MRIAS) Trial: Use of Baseline Multiparametric Magnetic Resonance Imaging and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate Biopsies. J Urol. 2020 May;203(5):910-917. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/31825297)]Hamoen EHJ, Hoeks CMA, Somford DM, van Oort IM, Vergunst H, Oddens JR, Smits GA, Bokhorst LP, Witjes JA, Rovers MM, Hulsbergen-van de Kaa CA, Barentsz JO. Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up. Eur Urol Focus. 2019 May;5(3):407-415. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/29331622)]Stavrinides V, Giganti F, Trock B, Punwani S, Allen C, Kirkham A, Freeman A, Haider A, Ball R, McCartan N, Whitaker H, Orczyk C, Emberton M, Moore CM. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. Eur Urol. 2020 Sep;78(3):443-451. [[PMC free](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443696/) [article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443696/)] [[PubMed](https://pubmed.ncbi.nlm.nih.gov/32360049)]Rajwa P, Pradere B, Quhal F, Mori K, Laukhtina E, Huebner NA, D'Andrea D, Krzywon A, Shim SR, Baltzer PA, Renard-Penna R, Leapman MS, Shariat SF, Ploussard G. Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta- analysis. Eur Urol. 2021 Nov;80(5):549-563. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/34020828)]Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW, Eggener S, Horwitz EM, Kane CJ, Kirkby E, Lin DW, McBride SM, Morgans AK, Pierorazio PM, Rodrigues G, Wong WW, Boorjian SA. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up. J Urol. 2022 Jul;208(1):19-25. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/35536148)] |  |

|  |  |  |
| --- | --- | --- |
|  | Chesnut GT, Vertosick EA, Benfante N, Sjoberg DD, Fainberg J, Lee T, Eastham J, Laudone V, Scardino P, Touijer K, Vickers A, Ehdaie B. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. Eur Urol. 2020 Apr;77(4):501-507. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7096768/)] [[PubMed](https://pubmed.ncbi.nlm.nih.gov/31874726)]Ashrafi AN, Shin T, Marien A, Clifford T, Shoji S, Iwata T, Iwata A, Oishi M, Chopra S, Cai J, Ukimura O, Bahn D, Gill IS, Abreu AL. Five-alpha reductase inhibitors in men undergoing active surveillance for prostate cancer: impact on treatment and reclassification after 6 years follow-up. World J Urol. 2021 Sep;39(9):3295- 3307. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/33683411)]Shore ND, Renzulli J, Fleshner NE, Hollowell CMP, Vourganti S, Silberstein J, Siddiqui R, Hairston J, Elsouda D, Russell D, Cooperberg MR, Tomlins SA. Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol. 2022 Aug 01;8(8):1128-1136. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204619/)] [[PubMed](https://pubmed.ncbi.nlm.nih.gov/35708696)]Van den Broeck T, van den Bergh RCN, Briers E, Cornford P, Cumberbatch M, Tilki D, De Santis M, Fanti S, Fossati N, Gillessen S, Grummet JP, Henry AM, Lardas M, Liew M, Mason M, Moris L, Schoots IG, van der Kwast T, van der Poel H, Wiegel T, Willemse PM, Rouvière O, Lam TB, Mottet N. Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. Eur Urol Focus. 2020 Mar 15;6(2):231-234. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/31248850)] |  |
| **Is the language/English quality of the article suitable for scholarly communications?** | The manuscript is well-written, clear, and maintains scholarly tone throughout.Minor typographical and grammatical improvements are suggested (e.g., "Smaple Size Determination" should be corrected to "Sample Size Determination").A final proofreading or professional language edit would enhance flow and precision in some sections. |  |
| **Optional/General** comments | This manuscript provides a meaningful contribution to the field of prostate disease research in African settings. Its findings have both scientific and public health relevance, especially regarding LDL-C as a potential marker in prostate screening protocols. With minorimprovements in language and further clarification in the abstract, this work is suitable for publication. |  |

|  |
| --- |
| **PART 2:**  |
|  | **Reviewer’s comment** | **Author’s comment** *(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)* |
| **Are there ethical issues in this manuscript?**  | *(If yes, Kindly please write down the ethical issues here in details)* |  |

**Reviewer details:**

**Indunil Karunarathna, University of Colombo, Sri Lanka**